ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Abstract Number: 0057

Molecular Profiling of Radiographic Axial Spondyloarthritis Patients Reveals an Association Between Innate and Adaptive Cell Populations and Therapeutic Response to Adalimumab
Abstract Number: 0058

Effect of Anti-inflammatory Drugs on Intestinal Epithelial Damage and Bacterial Translocation in the Adjuvant-induced Arthritis Model
Abstract Number: 0059

Deep Immune Cell Profiling of Tissue Microenvironment Using Imaging Mass Cytometry in Psoriatic Disease
Abstract Number: 0060

Lipidomic Profiling Identifies Different Expression of Oxylipins Between Synovial Tissue and Plasma of Patients with Rheumatoid and Psoriatic Arthritis
Abstract Number: 0061

Harnessing Spatially-Resolved Gene Expression to Characterize the Transcriptional Landscape of Psoriatic Skin
Abstract Number: 0062

Axial Spondyloarthritis and Its Related Immune-Mediated Diseases Share a Gut Microbiome Signature Besides Their Own Distinctive Profile
Abstract Number: 0063

Development of a Novel Cartilage Model Co-cultured with Conditioned Medium from Th17 Cells to Explore the Effect of IL-17A on Joint Tissue Remodeling
Abstract Number: 0064

Prevalence, Incidence and Predictor Features of Uveitis in Spondyloarthritis in a Canadian Cohort
Abstract Number: 0065

Altered Expression of Several miRNAs in Axial Spondyloarthritis Patients with High Disease Activity
Abstract Number: 0066

Characterization of αβTCR of HLA-B*27-Restricted CD8 T-Cell Clones Associated with Spondyloarthropathies
Abstract Number: 0067

Mendelian Randomisation Analysis of Protein Quantitative Trait Loci with Ankylosing Spondylitis Reveals Causative Involvement of Key Effector Proteins and Pathways
Abstract Number: 0068

Gut Bacteria Causing Ankylosing Spondylitis Identified Through Mendelian Randomization Studies
Abstract Number: 0069

First and Recurrent Thrombosis Risk After 3842 Patient-Years of Follow-Up: Prospective Results from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (
Abstract Number: 0070

Pregnancy Outcomes of Antiphospholipid Antibody Positive Patients: Prospective Results from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)
Abstract Number: 0071

Damage Accrual Measured by DIAPS in Antiphospholipid Antibody (aPL)-positive Patients: Results from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)

« Previous Page
1
…
5
6
7
8
9
…
132
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].